Magazine article from our research archive:
|
|
Nasal NK/T cell lymphoma presenting as a lethal midline granuloma
- Article from:
-
Indian Journal of Dermatology, Venereology and Leprology
- Article date:
-
March 1, 2008
- Author:
- Mehta, Vandana; Balachandran, C; Bhat, Sudha; Geetha, V; Fernandes, Donald
|
Copyright informationCopyright Medknow Publications Mar/Apr 2008. Provided by ProQuest LLC. (Hide copyright information)
|
Introduction
Lethal midline granuloma also known as 'Stewart's granuloma' or 'polymorphic reticulosis' refers to the presence and sequelae of a destructive lesion in the upper respiratory tract. According to literature, the majority of lethal midline granulomas are nasal NK/T cell lymphomas. [1] Nasal NK/T cell lymphomas are aggressive, locally destructive, midfacial, necrotizing lesions. Most of them were initially diagnosed as lethal midline granuloma, a term that is slowly being phased out. The nonspecific clinical symptoms constitute a major stumbling block in the early diagnosis and management of these lymphomas. Thus, we need to be aware of the uncommon presentations of this lymphoma. ...
|
CD13-positive anaplastic large cell lymphoma of T-cell origin--a...
Archives of Pathology & Laboratory Medicine;
December 1, 2000 ;
Popnikolov, Nikolay K; Payne, Deborah A; Hudnall, David; Hawkins, Hal K; Et al;
787 words
......of myelomonocytic-associated antigens in anaplastic large cell lymphomas (ALCLs), particularly those presenting in extranodal sites...Arch Pathol Lab Med. 2000;124:1804-1808) naplastic large cell lymphomas (ALCLs) are characterized by a pleomorphic appearance, sinus...
|
|
The new WHO nomenclature: Lymphoid neoplasms
Clinical Laboratory Science;
January 1, 2002 ;
Leclair, Susan J; Rodak, Bernadette F;
787 words
......follicular large cell lymphoma; FMC = follicular mixed cell lymphomas; FSC = follicular small cleaved lymphomas; LBL = lymphoblastic...concerning the subclassification of B cell lymphoma, mature T cell lymphomas, follicular lymphoma, and the use of clinical groupings...
|
|
Mechanism for Epstein-Barr Virus Protein's Role in Blood Cancers...
Ascribe Higher Education News Service;
December 23, 2005 ;
787 words
......immune system into cancerous cells, which can lead to B-cell lymphomas. Now, they have found that the viral protein--called EBNA3C...the development of therapeutics for treating EBV-related B cell lymphomas, says Robertson. This is especially important because a...
|
|
Nasal extranodal NK/T-cell lymphoma presenting as a perforating palatal...
Indian Journal of Dermatology, Venereology and Leprology;
May 1, 2006 ;
Patel, Vidula; Mahajan, Sunanda; Kharkar, Vidya; Khopkar, Uday;
787 words
...Introduction Nasal NK/T-cell lymphomas are aggressive, locally destructive...are collectively termed as NK/T-cell lymphomas. Thus, based on the clinical...orbit. Mature or peripheral NK/T-cell lymphomas account for only 10-15% of...
|
|
CD10 expression in primary intestinal large B-Cell lymphomas: Its clinical...
Archives of Pathology & Laboratory Medicine;
August 1, 2002 ;
Go, Jai Hyang; Yang, Woo Ick; Ree, Howe J;
787 words
......origin in primary intestinal large B-cell lymphomas. Design.-We performed immunohistochemistry...half of primary intestinal large B-cell lymphomas have a germinal center cell origin...patients with primary intestinal large B-cell lymphomas. (Arch Pathol Lab Med. 2002;126:956-9...
|
|
MabCampath(R) Shown to Be Effective in Treatment of Peripheral T-Cell...
PR Newswire Europe;
December 6, 2004 ;
787 words
......Hodgkin's Lymphoma (NHL). Peripheral T-cell lymphomas are often associated with unfavorable...cyclophospate (CP) and doxorubicin (Dox) in T-cell lymphomas, high efficacy of Fludara and CP (FC...chemoimmunotherapy in peripheral T-cell lymphomas except primary cutaneous T-cell ...
|
|
Comparative studies of somatic and ongoing mutations in immunoglobulin...
Archives of Pathology & Laboratory Medicine;
November 1, 2003 ;
Go, Jai Hyang; Kim, Dae Shick; Kim, Tae Jin; Ko, Young H; Et al;
787 words
...* Context.-Many diffuse large B-cell lymphomas (DLBCLs) of the stomach are believed to represent high...the stomach, a significant proportion of diffuse large B-cell lymphomas (DLBCLs) occur with a concomitant low-grade component...
|
|
Childhood cutaneous T-cell lymphomas on rise, experts say
Dermatology Times;
November 1, 2006 ;
Petrou, Ilya;
787 words
...PEDIATRIC FOCUS National report - The two forms of cutaneous T-cell lymphomas (CTCL), mycosis fungoides (MF) and Szary syndrome, are reported...adults than in children. But the incidence of cutaneous T-cell lymphomas appears to be on the rise in children and adolescents. This...
|
|
Comparison of Ataxia-Telangiectasia Mutated Protein Expression in Diffuse...
Archives of Pathology & Laboratory Medicine;
March 1, 2007 ;
Kim, Se Hoon; Cheong, June-Won; Park, Kwang Hwa; Kim, Tai Seung; Yang, Woo-Ick;
787 words
......nervous system diffuse large B-cell lymphomas (PCNS DLBCLs), the pathogenetic...98% of PCNS lymphomas are B-cell lymphomas.1 In addition, most of these Bcell lymphomas are diffuse large B-cell lymphomas (DLBCLs).2 There is a close...
|
|
Think infection in primary cutaneous B-cell lymphomas.(Clinical Rounds)
Skin & Allergy News;
March 1, 2005 ;
Jancin, Bruce;
332 words
......see regression of Borrelia-positive B-cell lymphomas [with] doxycycline-based therapy over...causative agent in some cutaneous B-cell lymphomas first emerged in the late 1990s with...specimens of confirmed cutaneous B-cell lymphomas contained specific DNA sequences belonging...
|
|
IDEC PHARMACEUTICALS AND GENENTECH EXPAND COLLABORATION TO INCLUDE...
PR Newswire;
February 20, 1996 ;
534 words
......IDEC-Y2B8, IDEC's radioconjugate for the treatment of B-cell lymphomas. IDEC expects to begin Phase II clinical testing of IDEC-Y2...genetically engineered monoclonal antibody for treatment of B-cell lymphomas. The addition of IDEC-Y2B8 to the collaboration should expand...
|
|
Immunomedics to Be Awarded U.S. Patent for the Treatment of B-Cell...
PR Newswire;
December 7, 2006 ;
787 words
......cover the use of the Company's product, hA20, which is a humanized anti-CD20 monoclonal antibody for the treatment of B-cell lymphomas, leukemias and autoimmune diseases. This patent strengthens our position for the advancement of a new anti-CD20 antibody...
|
|
Genetic signatures subclassify B-cell lymphomas.(Clinical Rounds)(cancer)
Skin & Allergy News;
March 1, 2005 ;
Jancin, Bruce;
608 words
......separate patients with cutaneous B-cell lymphomas into disease subgroups--and gene array...do not reliably separate cutaneous B-cell lymphomas from pseudolymphomas. Clonality assays...by a high false-negative rate in B-cell lymphomas. Plus, up to one-quarter of pseudolymphomas...
|
|
IDEC PHARMACEUTICALS INITIATES PIVOTAL PHASE III TRIAL OF IDEC-C2B8...
PR Newswire;
April 27, 1995 ;
732 words
......response in up to 200 patients with relapsed disease. B-cell lymphomas are cancers that affect the body's antibody- producing cells...human clinical studies include pan-B antibodies to treat B-cell lymphomas that the Company is developing in conjunction with Genentech...
|
|
TEL2 Gene Cooperates With MYC Gene To Provoke B-Cell Lymphomas; St. Jude...
PR Newswire;
March 21, 2005 ;
787 words
......development of B lymphoma. It was already known that many human B- cell lymphomas over-express the MYC gene, either because the tumor cells...of p53 function, Grosveld said. In fact, all TEL2/MYC B-cell lymphomas had lost their p53 function. Grosveld's team found that...
|
See all results.
Or, try our
Advanced Search.
|